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INTRODUCTION
Exposure of a host to a foreign antigen elicits an immune response
in which specific immunoglobulins and effector lymphocytes are produced
to identify and neutralize this foreign substance.

Elimination and des-

truction of the identified antigen proceeds through the functional limb
of the immune system, which includes immune effectors (complement, kinin,
coagulation, lymphokines, and lymphotoxin).

On activation of an immune

response, an inflammatory reaction is a result of the release of biologically active products from the immune effector systems.

Generally,

these products cause increased vascular permeability, smooth muscle contraction, and chemotaxis of leukocytes.

In the ensuing response, leuko-

cytic phagocytosis functions as the major defense mechanism for the removal and degradation of antigens.

In many bacterial infections, a hu-

moral response facilitates this phagocytosis through the production of
agglutinating and opsonizing antibodies, and by the amplification of the
inflammatory response through complement activation.

However, in many

respects the biosynthesis of antibodies is too slow and ponderous a mechanism for the purposes of host defense.

Therefore,initial biological re-

sponse at a local site of infection does not rely on a de novo immune reaction, but on innate (nonspecific activation of effectors) mechanisms that
trigger inflammation and enhance phagocytosis.

Both innate and immune

mechanisms in host defense have been reviewed (Humphrey and White, 1970;
and Davis et al., 1973).
1
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A variety of microbial factors and products cause potent biological changes in a host through initial and prolonged exposure.

Complement

(an alternate pathway) has been implicated as a humoral effector system
in reactions with microbial factors such as bacterial polysaccharides,
yeast cell walls, Gram-negative bacteria, and the endotoxic lipopolysaccharide (LPS) of certain Gram-negative species (Gotze and Muller-Eberhard, 1976).

The activation of complement by endotoxin has been implicated

as a potential pathologic factor in specialized tissues which are susceptible to damage by inflannnatory products (Mergenhagen et al., 1968; Gewurz
et al., 1971; and Synderman 1972b).

These pathological conditions include

both acute and chronic inflammation in tissues such as the glomerulus and
periodontium.

The presence of immunoglobulins to antigens, including endo-

toxin, have to be considered together with innate inflammatory mechanisms.
The participation of an endotoxin-activated complement system, in the presence or absence of an immune response to this antigen in generating biological activity is undefined.
The objective of this study is to compare in vitro complement generated chemotaxis in an immune system to chemotaxis in non-immune LPS-complement activation.

This comparison of chemotactic activity in two functional

complement pathways (immune system) to the alternate pathway (non-immune
activation), solely, will be related to in vivo LPS-complement participation
in inflammation and destruction in specialized tissues.

REVIEW OF THE LITERATURE
Endotoxic lipopolysaccharides and Gram-negative bacterial cells caused
potent biological reactions when injected into experimental animals.

The

activation of a histamine-releasing factor through a heat-labile serum enzyme has been implicated as the cause of the major physiological changes
of endotoxin: shock, fever, local inflammatory skin reactions, and death
(Greisman, 1960; Spink and Vick, 1961; and Weil and Spink, 1957).Complement activation was implicated in these in vivo reactions when all the
major physiological changes due to the presence of endotoxin were reproduced in laboratory animals by employing immune complexes (Stetson, 1964).
In addition, complement-induced anaphylactic shock was shown to simulate
endotoxin shock (Weil and Spink, 1957).

LPS was further demonstrated to

cause a significant decline in rabbit serum complement levels following
the injection of lethal doses (Gilbert and Braude, 1962; and Pearlman et
al., 1963).

In addition, the early phase of endotoxin shock in dogs could

be prevented by a cobra venom factor (CVF) decomplementation, which implicated the complement system as the mediator (Gewurz et al., 1970).
The endotoxic lipoplysaccharides of certain Gram-negative bacteria
have been demonstrated to function as activating factors of both the alternate pathway of complement fixation in immunoglobulin-independent reactions (figure 1), and the classic complement pathway (figure 2) in immunoglobulin-deperident reactions (Mergenhagen et al., 1973; and Westphal, 1975).
These two distinct pathways of complement activation have been observed in
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FIGURE 2
Classical Complement Activation
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normal vertebrate serum, and function in both specific and nonspecific
reactions in host defense.
The classical complement sequence is a multimolecular, self-assembling biological system which constitutes the primary humoral mediator of
antigen-antibody reactions (Muller-Eberhard, 1975; and Davis et al., 1973).
Operationally, this pathway can be divided into three functional units: Cl
(Clq-Clr-Cls), the recognition unit; the activation unit, C2, C3, C4; and
the membrane attack unit, C5b-C6-C7-C8-C9.

The first three components

function as a ca++- -dependent, trimolecular complex (Cl) which combines reversibly with immune complexes of IgG or IgM.

The Clq component possesses

recognition-binding sites for a receptor on the Fe portion of the innnunoglobulin.

Following binding, Clq undergoes conformational change that, in

turn, activates Clr as an enzyme.

Clr then cleaves s small fragment from

Cls, which activates the remaining fragment as a serine enzyme (Cls).
The second stage of the classical sequence involves the sequential ·
formation of two related enzymes initiated by Cls.

C4 is the natural sub-

strate of Cls, and is cleaved in large amounts into C4a and C4b.

The C4b

fragment can attach to the cell membrane (particle surface), and a small
percentage becomes bound.
neutralize certain viruses.

The resultant Cls-C4b site has the capacity to
In the following step, C2 is adsorbed by mem-

brane-bound C4b (Mg++- -dependent), and is cleaved by Cls into C2a and C2b.
The C2a fragment fuses with C4b to form another enzyme with C3 as its substrate (C3 convertase), while C2b enters the fluid phase.

C4b-C2a then

cleaves C3 into two fragments, C3a and C3b, allowing nascent C3b to associate itself with the activating enzyme.

C3a (anaphylatoxin) is given off

7

into the fluid phase, while C3b possesses a transient ability to attach
and opsonize cell membranes.

The latter has a binding site for lympho-

cytes and various phagocytic cells, and functions in immune adherence and
in enhancing phagocytosis.

The further association of C3b with C4b-C2a

on the membrane surface gives rise to a trimolecular complex with CS-cleaving activity (C4b-C2a-C3b).

CS is split into CSa (anaphylatoxin and chemo-

tactic factor), the fluid phase component, and CSb which possesses a transient binding site.
The third phase of the classical sequence is initiated by the cleavage
of CS, which initiates the formation of the stable CSb-C9 complex in both
the fluid phase and on the active site.

CSb sequentially activates, with-

out further enzymatic activation, the attachment of C6 and C7 (chemotactic
activity) with C8 and six molecules of C9.

The complex (CSb-C6-C7-C8-C9)

has the ability to alter cell membranes and cause irreversible damage.
The rapid decay of activated binding sites restricts complement action
I

to the immediate environment of the site.

Rigid control also limits the

time and space of classical complement reactions by the decay of C4b-C2a
and C4b-C2a-C3b, and through the actions of serum Cl inactivator and C3b
inactivator (Muller-Eberhard, 197S; and Mayer, 1970).

These classical

complement reactions have been studied in great detail and recently reviewed (Davis et al., 1973; Humphrey and White, 1970; and Muller-Eberhard,
197S).
Recent studies have demonstrated that the endotoxins of certain Gramnegative bacteria function as activating factors of the alternate pathway
of complement activation.

The ability of LPS to deplete complement com-

8

ponents was first observed to be a function of a newly discovered "properdin" system.

This system was described as a group of normal serum pro-

teins which interacted with zymosan, a variety of polysaccharides, and
lipopolysaccharide and resulted in the preferential consumption of "C3"*
in the presence of Mg++(Pillemer et al., 1954, 1955; Wedgwood et al., 1956;
Wardlaw and Pillemer, 1956; and Hinz et al., 1956).

This group of factors

appeared to mediate several diverse activities of normal serum such as, the
killing of Gram-negative bacteria, neutralization of certain viruses, and
lysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH).
A number of factors have been shown to activate the complement sequence without significant consumption of Cl, C2, and C4 (Sandberg et al.,
1970; and Gewurz et al., 1968b).

The absence of any reaction of endotoxin

with each of the terminal components indicated the need for serum factors
other than Cl, C2 and C4 in complement activation (Gewurz et al., 1968b).
These results were corroborated by similar experiments that firmly established the existence of a second complement pathway.

By demonstrating the

complement consuming ability of guinea pig y-1 antibodies, the ability of
C4-deficient serum to sustain complement activation, and the C3-cleaving
activity of LPS in C2-adsorbed guinea pig serum, an alternate pathway was
believed to exist (Frank et al., 1971; Sandberg et al., 1970, 1971; and

*C3 was an early designation of components C3 to C9.

9

Marcus et al., 1971).
Through a second series of related investigations with cobra venom
factor (CVF), the "C3 activator system" was identified as an alternate
complement pathway (Muller-Eberhard & Gotze, 1971). Recent investigations
have identified the properdin and activator systems as an identical pathway, and has currently led to the postulation of a plausible molecular
concept of alternate pathway activation (Muller-Eberhard, 1975; and Gotze

& Muller-Eberhard, 1976).

Activation of this pathway has been demonstrated

to occur through a number of substances including LPS, plant polysaccharides, a number of polymeric substances, T cell-independent antigens, B cell
mitogens, levan-polymerized flagellin, dextran sulfate, and pokeweed mitogen (Mergenhagen et al., 1969, 1973; Burger et al., 1975; Radding et al.,
1973; and Bitter-Suermann et al., 1975).

Immunoglobulin activation of the

alternate pathway is not required, but does occur frequently.

Guinea pig

y-1 and y-2, as well as rabbit IgG, have the ability to activate the alternate pathway through a site in their F(ab')

2

fragment (Burger' et al., 1975;

Osler et al., 1969; Reid, 1971; Sandberg et al., 1972, 1970, 1971; and
Schur & Becker, 1963).

Aggregates of human IgA

1

and IgA

2

are endowed with

the same capacity, while human IgG aquires the function only under exceptional circumstances (Gotze & Muller-Eberhard, 1976).
In a yet unknown manner, an alternate pathway activator causes the
conversion of the properdin precursor to active properdin (P). However,
recent evidence indicates that there are several factors that preceed properdin utilization (table 1) (Muller-Eberhard, 1975).

Following the contact

Table l
Nomenclature and Proteins of the Properdin System.
Molecular
Weight

Serum
Cone.
(ug/ml)

Protein Component

Symbol

Initiating Factor

lF

Properdin

p

212,000

C3
C3Pa,Pa,,orB

180,000

1,104-1,373

93 ,,000

143-226

Pase,orO

24.000

1-5

C3b INA

100,000

30-50

B1H

150,000

133

3rd Complement Component
C3 Proactivator
C3 Proactivator Convertase

C3 I: nact i va tor
C3 l:nactivator Accelerator

160-180,000

20-50
25

(renroduced with modifications from Muller-Eberhard, 1975)

I-'
0
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with essential structures of the activating particle, an activated initiating factor (IF) interacts with Pa (factor B), Pase (factor D), and native
C3 (in the presence of Mg++) to generate a C3 convertase (figure 1).

Pa

and C3 interact without enzymatic cleavage and can be recovered intact after
activation (Fearon & Austen 1975; Nicholson et al., 1975; and Vogt et al.,
1975).

This soluble enzyme acts only on C3, and can deposit C3b onto the

surface of the activating substance.

The latter fragment subsequently a-

quires a transient site for various acceptors (Muller-Eberhard, 1966), a
stable binding site for immune adherence reactions (Eden et al., 1973; Lay

& Nussenzweig, 1968; and Vogt et al., 1975), a site which interacts with
Pa and Mg++, and a binding site for activated properdin (Fearon & Austen,
1975).
In this initial cleavage of C3, C3b is also deposited in the fluid
phase (with C3a), which leads to the further formation of a soluble, labile
C3 convertase and a bound, labile C3-C5 convertase (Gotze & Muller-Eberhard,
1976).

Analogous to classical C4b-C2a, bound and soluble C3b. display a Mg++

-dependent affinity for PA in the formation of a reversible inactive complex
(Medicus et al., 1976; Nicholson et al., 1975, and Vogt et al., 1975, 1976).
This complex is then subject to the hydrolytic action of Pase, which cleaves
a fragment from Pa, producing a complex (C3b-Bb) possessing C3-cleaving activity (active site on Bb).

This convertase has been shown to operate in a

positive feedback mechanism through the generation of C3b fragments (MullerEberhard & Gotze, 1972; Gotze & Muller-Eberhard, 1976; and Brade et al.,
1974).

Evidence suggests that at least two spacially arranged molecules

12
are necessary for C3b-Bb expression of CS convertase activity (C3b -Bb, where
n

n>l).

CS cleavage, as in the classical pathway, activates terminal compo-

nents involved in the membrane attack unit.

Both C3 and CS convertase of

the alternate pathway are analogous to the classical pathway enzymes, and
function in producing large amounts of biologically active products (C3a
and CSa) in the fluid phase.
It is now clear that properdin is utilized in the final steps of this
pathway.

It occurs in serum in a precursor form, and is able to form a

-P-dependent C3 convertase with Pa, Pase, C3, and Mg++ (Gotze & Muller-Eberhard, 1976).

Evidence suggests that surface-bound CS convertase (C3b -Bb)
n

is the properdin activating factor, and that P also participates in a fluid
phase C3 convertase.

The attachment of P to the bound CS convertase in-

creases the half-life of the enzyme by conferring stability on the association of C3b-B and by retarding spontaneous decay (Fearon & Austen, 197S;
and Vogt et al., 1974, 1976).

The stabilized enzyme (C3b -Bb-P)acts on
n

both C3 and CS, and can undergo reverse assembly by loss of factor B. This
P-bound site can attain enzymatic activity by the reaquisition of B in the
presence of Mg++ and Pase (factor D).
This complex pathway has, at present, three known modes of regulation.
C3-CS convertase decays spontaneously due to the loss of Bb.

Secondly, sol-

uble C3b can actively disassemble P-stabilized CS convertase by releasing Bb.
The third is by the action of a serum enzyme, C3b inactivator (C3b INA),
which cleaves bound C3b into two smaller fragments, and causes the release
of bound P (Medicus et al., 1976; and Gotze & Muller-Eberhard, 1976).

Op-

timal inhibitory regulation of C3b inactivator requires the simultaneous

13
presence of yet another serum protein.

The effector is a !Os,

S1H-globulin

(C3b INA accelerator), which operates in trace amounts (Whaley and Ruddy,
1976; Gitlin et al., 1975; Lachmann and Muller-Eberhard,'1968; and Nilsson

& Muller-Eberhard, 1965).
Thus, through the activation of either complement pathway, C3 and CS
convertase, as well as the membrane attack unit, can be constructed and activated.

The major differences of the two pathways reside in the mode and

specificity of initial activation, and in the use or bypassing of components
Cl, C2, and C4.
Investigations utilizing reactions of Gram-negative bacteria or LPS
with complement have involved bactericidal action, significant complement
consumption profiles, reactivity in complement-deficient sera, and the generation of biologically active products (Wardlaw, 1964; Bladen et al., 1967;
Gewurz et al., 1968a,c, 1969b; Mergenhagen et al., 1969; and Fine, 1972 and
1974).
The endotoxin from a variety of organisms (Veillonella alcalescens,
Serratia marcescens, Salmonella typhosa, and Escherichia coli) has demonstrated the ability to activate complement when incubated with guinea pig,
human, and primitive vertebrate sera (Pillemer et al., 1955; Gilbert and
Braude, 1962; Miller et al., 1966; Gewurz et al., 1968; and Day et al., 1970).
Microgram amounts of LPS caused significant depletion of complement levels in
all species that exhibited antibody-induced hemolytic activity (Day et al.,
1070).

Complement activation was evident in these reactions by the presence

of multiple lesions on the surface of LPS particles.

14
Complement fixation by LPS has been examined in view of the initiation of biological reactions, and in comparison to classical complement fixation.

It was reported that factors exist (alternate pathway proteins) in

normal guinea pig and human sera to initiate complement fixation upon incubation with LPS in the absence of exogenous antibody (Bladen et al., 1967;
Day et al,, 1970; Gewurz et al., 1968a and 1971).

Endotoxin depleted the

six terminal complement components (C3-C9) with minimal consumption of Cl,
CZ, and C4 (Gewurz et al., 1968b).

In addition, Gewurz et al., (1968b and

1971) have reported that the LPS of V. alcalescens consumed significantly
greater amounts of terminal components than either the zymosan activated alternate pathway, or immune complex activated classic pathway.
These reactions were further examined utilizing sera from man, pig,
and cow with developmental agammaglobulinemia (Gewurz et al., 1969a and
1970).

Depletion of complement ensued in each of the vertebrate sera, ex-

cept human, when challenged with LPS, and the percent fixation was comparable to irnmunoglobulin-normal control animals.

However, the lower level of

complement consumption in human agammaglobulinemic, Cl-deficient, and C2deficient sera implied the requirement of an efficient use of anti-LPS immunoglobulins with Cl, CZ, and C4 in the formation of an intermediate C3 convertase (Gewurz et al., 197la,b; Synderman et al., 197lc).
Further examination of LPS-vertebrate complement reactions demonstrated
complement activation and efficient consumption of terminal components in
the absence of C4b-C2a (Marcus et al., 1971; and Frank et al., 1970).

This

supported the concept of alternate pathway activation in the absence of im-

15
mune complexes.

The minimal consumption of Cl, C2, and C4 in LPS-guinea

pig serum incubations was determined to be the result of a natural antibody.

In addition, chelation of human serum with EGTA (binds Ca++ more av-

idly than Mg++) inhibited classical complement activation, but allowed alternate pathway activation when challenged with erythrocyte-labeled LPS
(E-LPS) (Fine, 1972 and 1974; Forsgren et al., 1975).

Thus, LPS activates

the alternate pathway of complement fixation, and is capable of terminating
in a membrane attack unit.independent of antibody mediation.
Ample evidence exists to demonstrate the role of complement (C5b-6-78""9J :tn bactericidal reactions initiated by immune complexes (Muller-Eberhard, 1966 and 1975; Rapp and Boros, 1966; and Nelson, 1965).

LPS is also

capable of acting as a substrate for this reaction, which consumes significant amounts of the six terminal components (Boros, 1964; Radding et al.,
1966; Bladen et al., 1966; Gewurz et al., 1970 and 1971; and Mergenhagen et
al., 1968).

The incubation of guinea pig sera with LPS or Gram-negative

bacteria regularly induces lesions on the particle surface, which are characteristic of complement activation (Bladen et al., 1967; and Mergenhagen
et al., 1969).

When guinea pig sera was treated with a number of complement

inhibitors, the loss of.the ability to lyse sensitized red blood cells was
associated with the absence of lesions on the LPS surface of V. alcalescens
(Bladen et al., 1967; and Mergenhagen et al., 1968).

Lesions on endotoxin

are consequent to the activation of complement and the interaction of multiple complement components.

In the formation of such lesions, given amounts

of LPS consumed greater quantities of C3 to C9 than either immune complexes
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or aggregated human gammaglobulin (Gewurz et al., 1969b).
Activation of the clotting system by LPS-complement activation is another factor in the pathological effects of LPS (Thomas, 1954; Mergenhagen
et al., 1969).

The injection of LPS into a suitable host causes a pro-

found thrombocytopenia, which is characterized by the deposition of agglutinated platelets in the liver, spleen, and lung (McKay and Shapiro, 1958;
Stetson, 1951).

In vivo reactions of LPS cause platelet degranulation and

release of factors (histamine and platelet factor three, P.F.3) through a
heat-labile, cation-dependent, plasma system (Horowitz et al., 1962; Des
Perez and Bryant, 1966).

Complement was implicated as the mediator of the

LPS-platelet reaction, and a Mg++ requirement implicated the alternate pathway as the apparent in vitro mechanism (Spievogel, 1967; Nelson, 1965; Sequieria and Nelson, 1961; Gocke and Osler, 1965; Sandberg et al., 1971;
Zucker and Grimm, 1974; and Pfueller and Luscher, 1974).
Endotoxin activation of the clotting mechanism appeared to require C3,
C3 proactivator (Pa), and possibly properdin as necessary factors (Zucher
et al., 1974; and Kane et al., 1973).

However, a fault in the clotting mech-

anism of C6-deficient rabbits implicated the membrane attack unit from either pathway as the mediator of platelet degranulation (Zimmerman, 1971).
The reaction appears to be a noncytolytic event (lack of CS and C9) in
which C3, CS, C6, and C7 are required (Kane et al., 1973; and Graff et al.,
1976).

Thus, the aggregation of platelets, degranulation, and activation

of P.F. 3 by endotoxin-complement interaction may represent a possible mechanism of the pathological intravascular coagulation seen in Schwartzman-
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type reactions and Gram-negative sepsis (Zimmerman, 1973; and Brown and
Lachmann, 1973).
Endotoxic lipopolysaccharides of Gram-negative bacteria are macromolecular complexes which are composed of two chemical moieties: a complex heteropolysaccharide and a lipid portion, lipid A (Shands, 1971;
and Gewurz et al., 1971).

LPS is rich in antigenic determinants with

which immunoglobulins frequently react (Neter, 1969).
A number of morphological studies on LPS of various bacterial genera have shown superficial structural similarities in a trilaminar arrangement, which could be connnon to all gram negative lipopolysaccharides
(Shands, 1971; Rothfield et al., 1966; Bladen et al., 1967; De Petris,
1967; and Knoz et al., 1967).

This structure consists of linear repeat-

ing oligosaccharides ("O" antigen) linked to a core polysaccharide, which
is covalently linked to the lipid A moiety (Luderitz et al., 1966b). Lipid
A is a highly substituted, long chain fatty acid derivitive of a phosphorylated hexosamine-disaccharide backbone: 4-phosphoglucosaminyl-B-1,
6-glucosamine-1-phosphate (Westphal, 1975).

The core polysaccharide forms

an ester bond to the hexosamine unit connnonly with KDO (2-keto-3-deoxyoctanate).

The polysaccharide contains five sugar constituents in most en-

dotoxins, and commonly consists of a heptose, glucose, galactose, and glucosamine (besides KDO) (Westphal, 1975).

Three hydroxyl groups on the

disacchariqe backbone are esterified with !auric (c 12 ), myristic (c14 ),
and palmitic (c16 ) acids.

An ester linkage to the KDO unit is formed at

a fourth hydroxyl group (Luderitz, et al., 1973).
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It appears that the polysaccharide components of the LPS molecule
do not play any specific role in endotoxicity (Galanos et al., 1971).
However, the polysaccharides attached to lipid A may render it more soluble by influencing the conformation, which indirectly effects endotoxic
reactions (Galanos et al., 1972; Morrison, 1976; Loos et al., 1974; and
Lachman and Nicol, 1974.

Purified suspensions of

"O"

antigens and core

polysaccharide have been found to be ineffective in alternate complement
pathway activation (Mergenhagen et al., 1961).
Complement activation is not a property connnon to all lipopolysaccharides, though, the isolated lipid A from both active and non-active
endotoxin is strongly toxic and anticomplementary when solublized by a
suitable carrier (Galanos, 1971).

The reaction with complement does not

result in any chemical or compositional changes, but does result in the
loss of solubility in water and loss of biological activity.
The participation of complement in infiammation and tissue destruction has been partially attributed to the production of anaphylactic and
chemotactic factors through both pathways (Mergenhagen, 1970,1972a; MullerEberhard, 1972a; Budzko et al., 1971; and Hugli, 1975b,a).

The developing

sequellae of reactions, following the injection of immune complex-adsorbed
serum in guinea pigs, was first proposed to be the effect of a toxic factor (anaphylatoxin) generated from the serum (Freidberger, 1910). Generally, anaphylatoxin is a pharmacologically active substance that causes contraction of the guinea pig ileum, is blocked by anti-histamines, increases
vascular permeability, and degranulates mast cells (Mergenhagen et al.,
1969).
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The function of complement in anaphylatoxin generation was first
recognized by Osler et al., (19S9a,b).

Hemolytic complement fixation

was necessary for rat skin-bluing activity when immune complexes, agar,
inulin, dextran, liquoid, and zymosan were incubated with rat serum.
Through the inhibition of complement activity, the immune aggregates were
unable to produce anaphylatoxins upon incubation.

Cl esterase activation

of guinea pig sera also generated factor (s) that fulfilled the established critereon for anaphylatoxin (Rattnoff and Lepow, 1963; and Dias
Da Silva and Lepow, 1966a).

The reactions were dependent on the parti-

cipation of complement factors beyond Cl, C2, and C4.
In separate reactions, purified complement components were incubated
with a number of factors (LPS, CVF, immune aggregates, and polysaccharides)
which stimulated the release of anaphylatoxin.

This factor could be pro-

duced by tryptic cleavage of CS, but was also generated in solutions containing only Cl, C2, C4, and C3 (Jensen, 1966, 1967; Dias Da Silva and
Lepow, 1966a, 1967; and Cochrane and Muller-Eberhard, 1968).

The latter

stimulated the in vitro degranulation of mast cells, and was unaffected
by the addition of CS.

Further examination of these reactions revealed

that the fluid phase anaphylatoxin was generated from a reaction of Cl,
C2, C4, and C3.

This factor was cleaved from C3 (C3a), and had an approx-

imate molecular weight of 6800 (Shin et al., 1969a; Dias Da Silva et al.,
1967; and Cochrane and Muller-Eberhard, 1968).

Utilizing sheep red blood

cell-bound complement intermediates (C2a-C4b-C3), anaphylatoxin was generated from CS (CSa), and caused contraction of the guinea pig ileum. The
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cleavage of CS appeared to be dependent upon the formation of a cell-bound
CS convertase, and generated a factor (lS,000 daltons) with both anaphylactic and chemotactic abilities.

Thus, C3a and CSa serve as anaphyla-

toxins when activated by known initiators of the classical complement sequence (Mergenhagen et al., 1969).
The experimental evidence that endotoxins induce anaphylatoxins from
whole serum strongly indicates complement factors identical to those mentioned previously, and have become apparent with the current molecular model
of alternate pathway activation.

The incubation of LPS

(y_.

alcalescens and

E. coli) in rat plasma and guinea pig sera produced the capacity to contract the guinea pig ileum in a manner analogous to anaphylatoxin (Greisman, 1960; and Lichtenstein et al., 1969).

A positive correlation was

made between LPS-activation of terminal complement components and the appearance of anaphylactic activity.

Furthermore, these reactions were in-

hibited by anti-histamines and complement inactivation.
Several investigators have determined that LPS-complement activation
cleaves small molecular weight fragments from guinea pig C3 and CS (C3a
and CSa), which retain anaphylactic and chemotactic activity (Jensen et al.,
1969; and Synderman et al., 1969).

Incubation of LPS, lipid A, or zymosan

in human, guinea pig, or hamster sera generates C3a and CSa via the alternate pathway (Brade and Vogt, 1972; Hook, 1970; and Dierich et al., 1973).
The anaphylatoxins released in these reactions caused the degranulation
of mast cells and human basophilic leukocytes, releasing histamine and heparin (Hook, 1970; Muller-Eberhard, 197S; Gewurz et al., 1971; Johnson et al.,
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1975; and Hook et al., 1975).

Isolated C5a from LPS-stimulated serum has

been shown to cause typical anaphylactic responses.

The subcutaneous in-

jection of this factor in rabbits and rats produced an intense inflammatory reaction that resembled the Arthus phenomenon in lesion formation
and time course (Synderrnan et al., 1971, 1969; and Jensen et al., 1969).
In addition to C3a and C5a, LPS-complement reactions liberate or activate a histamine-heparin releasing factor with vasoactive properties.
The expression of vasoactivity by this factor, a 60,000 molecular weight
~-2

globulin, is dependent on complement initiation, but is inconsistent

with published data on complement anaphylatoxins (Hook et al., 1972).
Both C3a and C5a have been recognized in human serum, but were considered insignificant due to negligable biological activity in experimental systems (Muller-Eberhard and Vallota, 1971; and Bokisch and MullerEberhard, 1970).

The isolation and characterization of an anaphylatoxin

inactivator (AI) revealed a control mechanism for human complement anaphylatoxins.

The factor occurs in trace amounts as a carboxypeptidase

that functions by the removal of the C-terrninal amino acid residue on both
C3a and C5a (Vallota and Muller-Eberhard, 1973; and Bokisch et al., 1975).
The removal of AI allowed the generation of anaphylatoxins through both
complement pathways by LPS, inulin, and immune complexes.

It was deter-

mined that human anaphylatoxins are not significantly different from those
of other mammalian species, and that C5a (16,500) is one thousand fold
more biologically active than C3a (9,000), on a molar basis.
Polymorphonuclear leukocyte (PMN) accumulation follows the intra-
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dermal injection of microgram amounts of endotoxin, and is one characteristic pathological change induced by LPS (Stetson, 1951; and Thomas, 1954).
Similar i.p. injections of sub-microgram amounts caused

a dramatic

in PMN accumulation in peritoneal exudates (Fruhman, 1959).

increase

The mechanism

mediating these responses was examined, in vitro, following the development of a suitable assay by Boyden (1962).

The assay measured leukocyte

migration through a Millipore filter within an acrylic diffusion chamber.
Innnune complexes incubated in guinea pig serum caused the chemotaxis
of PMN leukocytes through the activation of a heat-labile serum enzyme
system (Boyden, 1962).

Similarly, aggregated human gamma globulins alone

could not generate chemotaxis, but produced this activity when incubated
in rabbit serum (Keller and Sorkin, 1965).

Further studies determined

that a chemotactic component was derived from the complement system, and
is composed of a trimolecular complex of C5b-6-7, with a molecular weight
of 300,000 (Ward et al., 1965, 1966).

A second factor derived from C3

(C3a), with a molecular weight of 8,000, also exhibited chemotactic attraction to rabbit PMN leukocytes (Ward, 1967).
The incubation of microgram amounts of LPS from V. alcalescens and S.
marcescens in human, guinea pig, and rabbit serum induced chemotactic activity for PMNs (Synderman et al., 1968).

Various inhibitors of comple-

ment also halted chemotaxis in LPS-stimulated serum.

The active component

was identified as a peptide with a molecular weight of 15,000 which was
antigenically identical to the complement anaphylatoxin, C5a (Synderman
et al., 1968, 1969; and Shin et al., 1968).

C5-6-7 and C3a chemotactic

factors were found to possess weak biological activity in the chemotactic
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attraction of PMN leukocytes (Shin et al., 1969b).
The intradermal injection of CSa in rabbits caused increased vascular permeability and neutrophil accumulation (Jensen et al., 1969; and
Shin et al., 1969b).

This led to the hypothesis that complement activa-

tion, as a biological effector of inflanunation through anaphylactic and
chemotacic activities, mediates certain pathologic effects of bacterial
LPS (Ward and Newman, 1969).
Synderman et al., (1971) investigated the role of C5a in the early
accumulation of PMNs in inflammatory exudates.

A 0.5% glycogen solution

was injected i.p. in guinea pigs, and exudates were extracted at 30 minutes, 1, 2, 3, 4, 5, 6, 27, and 48 hours.

PMN levels increased to a max-

imum from 2 to 6 hours (260 x 10 6 /ml), and then decreased to 48 hours.
The chemotactic factor was present after 30 minutes, and increased to a
maximum at 2 hours.

CS-deficient mice, highly susceptible to microbial

infection, were unable to duplicate this experiment.
Guinea pig, mouse, and human mononuclear leukocytes also respond chemotactically to C5a, in vitro.

This factor may be responsible for mono-

cyte accumulation in wound healing, and could mediate tissue damage in
sensitive tissues (Synderman et al., 197lb, 1972a, and 1975; and LettBrown, 1976).
Human basophilic leukocytes have been found to respond chemotactically
to a number of factors, including CSa.

In mixed populations of leukocytes,

a 5-10% basophil population responded to zymosan, LPS, and trypsin-generated C5a, together with neutrophils and monocytes (Kay and Austen, 1970;
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and Ward et al., 1975).
Eosinophils have also been demonstrated to respond chemotactically
to a trypsin-derived C5a in mixed population of leukocytes.

When the

eosinophil population exceeded 10% in the Boyden test chamber, C5a selectively attracted these cells with minimal migration of neutrophils (Kay
et al., 1973).
Thus, C5a generated from both complement pathways mediates the directed migration of blood leukocytes, especially PMNs and monocytes.

This

has been proposed as the second major biological activity of complement
as a mediator of the inflammatory response (Muller-Eberhard, 1972a; and
Mergenhagen, 1972).

MATERIALS AND METHODS
Organism and growth conditions
Veillonella alcalescens Cl, a Gram-negative anaerobe (diplococcus)
isolate from sheep rumen, was supplied by Dr. E.A. Delwiche of the College
of Food Sciences, Cornell University in Ithaca, New York. Initial cultures
(1.8 liters) were grown in a pre-reduced lactate medium in 2000 ml flasks
for seventy-two hours at 37°C. This liquid medium was overlayed with sterile paraffin oil (degased) to insure reduced conditions under incubation.
This medium was prepared according to Virginia Polytechnic Institute specification (VPI Anaerobe Lab Manual, 1975), and was used within one day
of preparation.

The medium was a peptone-yeast-lactate (PY-L) with the

following formula: 10 gm peptone (Difeo), 10 gm yeast extract (BBL), 4 ml
resazurin solution (0.25 mg per ml H 0), 40 ml salts solution (0.2 gm
2
CaC1 , 0.2 gm MgS0 7H 0, 1.0 gm K HP0 , 1.0 gm KH Po , 10 gm NaHC0 , and
2
4
2
2
4
2 4
3
2.0 gm NaCl per 1000 ml distilled H 0), and 9 ml 85% lactic acid added to
2
1000 ml distilled water. The pH was adjusted to 7.0 with 8N NaOH and boiled
until the resazurin indicator became colorless.

Then 0.5 gm cysteine hydro-

chloride (Eastman) was added as a reducing agent, the pH readjusted to 7.0,
and the medium autoclaved.

Cells were harvested, washed in cold saline

(0.15M NaCl), resuspended in 40 ml sterile skim milk, and lyophilized.
Viable cultures were maintained on pre-reduced brain-heart infusion agar
plates containing 3.7% B.H.I., 0.5% yeast extract, 0.4% resazurin solution,
and 0.05% cysteine hydrochloride.

The plates were incubated in vented Gas
25
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Pack anaerobic jars (BBL) at 37°C, and were transferred once every three
days.

Anaerobic conditions in the jar were established by flushing twice

with anaerobic grade co2, and filling the jar with gas composed of 10.34%
co , 10.0% H , and the balance N •
2
2
2

Disposable anaerobic indicators (BBL)

with methylene blue and the resazurin in the media were used to monitor
anaerobic conditions in the jar.
Extraction of bacterial endotoxin
For the routine extraction of endotoxin from Veillonella alcalescens,
three flasks, each containing 250 ml of PY-L, were innoculated from single
colonies of V. alcalescens and incubated at 37°C for forty-eight hours.
These cultures were used to innoculate six (1 starter culture per 2 liters)
liters of PY-L, which were subsequently incubated for seventy-two hours at
37°C.

The cells were grown to 10 9 per ml, harvested with a Beckman J-21

centrifuge at 15,380 x g for thirty minutes, washed three times in cold saline
(0.15M NaCl), and resuspended in 40 ml of saline.

Cell walls were disrupted

by sonication (Blackstone) at two minute intervals, followed by two minutes
cooling at 4°C, for a total of twenty-two minutes of actual sonication.

This

procedure was performed with extreme care to generate a minimum amount of
heat to the cell walls by using ice baths.

Cell lysis was measured by phase

contrast microscopy and viable counts (pour-plate technique),

Cell wall de-

bris was harvested by centrifugation (Beckman J-21) at 27,300 x g for two
hours.

The cell wall pellet was resuspended in sterile distilled water and

centrifuged.

This washing procedure was repeated six times, and the pellet

of cell wall material was finally resuspended in 50 ml of distilled water.
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Endotoxin was extracted by the phenol-water method of Westphal (1952,1971),
as diagramed in figure 3.

The yield of purified LPS from whole bacterial

cells was approximately 1.72% (9.8 mg of endotoxin) of the dry weight.
Experimental animals
Young adult female guinea pigs (Scientific Small Animal), from 500 to
700 grams, were housed in a thermostatically controlled and humidified room,
with a diurnal variation of light, at Loyola University Dental School Animal Care Facility.

They were contained in large metal cages with mesh bot-

toms, and were fed Purina guinea pig chow and water (supplemented with ascorbic acid) ad libitum.

Adult New Zealand rabbits, from 2 to 3 kilograms,

were also housed under similar conditions.
ina rabbit chow and lettuce ad libitum.

They were watered and fed Pur-

Only clinically healthy rabbits

were considered for use in experimental studies.
Source of complement

Complement was collected from healthy, female guinea pigs by cardiac
puncture.

An intravenous infusion set (19 gauge, 7/8 inch needle) was con-

nected to a #5 1/2 rubber stopper with a glass-tube lead for attachment to
a small vacuum pump.

The complete sterile apparatus was aseptically at-

tached to a 50 ml conical centrifuge tube (I.E.C.), and blood was collected
from the guinea pigs under vacuum (2 psi).

The blood was allowed to clot

at room temperature for fifteen minutes, the tubes rimmed with sterile applicator sticks, and centrifuged at 160 x g for thirty minutes in an International Clinical Centrifuge (I.E.C.).

The separated serum was col-
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FIGURE 3
Phenol-water extraction of endotoxin
50 ml of an 89% phenol solution, heated to 56°C, was added
to the 50 ml cell wall suspension, and heated for thirty
minutes at 56°C with continuous stirring.

The suspension was cooled to 4°C and centrifuged at 27,300 x g
for one hour, resulting in a distinct phase separation of
phenol and water.

Aqueous phase I

Phenolrh•••

50 ml distilled
water added to
phenol phase, heated
for 30 min. at 56°C
with stirring, and
cooled to 4°C.

Centriflgation was
repeated at 27,300
x g for 1 hour.

Aqueous phase II

/i
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Phenol phase
was discarded.

The aqueous phases (upper phase) were dialyzed against
distilled water to remove phenol, as indicated by the
lack of detectable odor.

i

Endotoxin was precipitated from the water by the addition
of granular sodium acetate (Sigma) to a final concentration
of 0.15M and absolute ethanol dropwise to a final volume
concentration of 68% while stirring at 4°C.

i

The solution was kept at 4°C over night to allow precipitation.

i

The precipitate was separated by centrifugation at 1000 x g
for thirty min.

l

The pellet from centrifugation was resuspended in 25 ml
of distilled water and dialyzed against distilled water
to remove traces of ethanol.

i

Lyophilization yielded the purified endotoxin.
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lected by sterile Pasteur pipets, placed in sterile tubes, and immediately
frozen at -58°C (Revco).

When approximately 30 ml of serum had been col-

lected, it was pooled, divided into 1 ml aliquots, and frozen at -58°C.
Whole guinea pig serum was used as the complement source in all assays
performed.
Source of antiserum
Anti-y_. alcalescens serum was prepared by injecting six female guinea
pigs with heat-killed whole cells of V. alcalescens Cl,

The saline cell sus-

pensions (0,15M NaCl) were emulsified in complete Freund's adjuvant (Difeo),
and injected at a rate of three injections per week for five weeks.

The in-

jections consisted of increasing doses from 0.1 mg to 1,0 mg of dry whole
cells, and were administered by intramuscular and subcutaneous routes, alternately.

At the end of thirty-five days the animals were bled (36th day).

Six days later they were boosted with 1.0 ml of a 1 mg per ml suspension of

y_. alcalescens subcutaneously.

The following day they were again boosted in-

traperitoneally with 1.0 ml of the same suspension. Six days later they were
again bled. Following this schedule, the guinea pigs were boosted with the
cell suspension and bled on alternate weeks until approximately 40 ml of antisera had been collected (Hagen, 1972). Serum was separated and collected
as already described, and was frozen in large tubes at -58°C. All injections
were performed with disposable 3cc syringes with 22 gauge, 1 1/4 inch needles.
Pre-immunization bleedings were performed with a guinea pig bleeding apparatus, which used a 15 psi vacuum to collect blood from the tarsus vein. Antisera was collected by cardiac puncture.

All samples with a passive hemag-

glutination titer of 5120 or above, were pooled, heat-inactivated at 56°C for
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thirty minutes, decanted into vials, and frozen at -58°C until used (Weir,
1967).
Rabbit polymorphonuclear leukocytes
Polymorphonuclear leukocytes were collected from peritoneal exudates by
a modified method of Sbarra and Karnovsky (1959).

A 110 ml solution of 8%

casein (Matheson, Coleman, and Bell) in saline (0.15M NaCl), supplemented
with 50 µg neomycin per ml, was injected intraperitoneally with a 50cc syringe
and 18 gauge needle.

Approximately eighteen hours later, the cells were col-

lected by injecting 150 ml of heparinized saline (10 units per ml) into the
peritoneal cavity.
point in the cavity.

The exudate was immediately aspirated from the lowest
An 18 gauge, 1 1/2 inch needle mounted in heparinized

rubber tubing was connected to a glass tube lead into a #5 1/2 rubber stopper
as previously described.

This vacuum device was aseptically inserted into an

I.E.C. conical centrifuge tube, and was used to aspirate fluid from the rabbit peritoneum.

The leukocyte suspension was harvested by centrifugation for

ten minutes at 160 x g, and resuspended in Gey's balanced salt solution (Difeo)
containing 2% BSA (Difeo), 50 µg streptomycin per ml, 50 units penicillin per
ml, and 10 units heparin per ml (Synderman et al., 1968).

Leukocytes were

counted by standard clinical procedures utilizing a Neubauer hemacytometer
(American Optical Co.), and adjusted to 3 x 10 6 cells per ml with Gey's medium.
Differential counts of two hundred Wright stained cells determined the number
of PMN leukocytes in suspension (Brown, 1975).

The counts ranged from 86 to

95.5% PMNs, with minimal numbers of monocytes, lymphocytes, and eosinophils.
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Chelation of complement and antisera
Pooled guinea pig complement and anti-V. alcalescens sera were chelated
with ethyleneglycol-bis(S-amino-ethyl ether) N,N'-tetra acetic acid (EGTA,
Sigma) according to the procedure of Fine (1972, 1974; and Forsgren et al.,
1975).

Chelation with lOmM MgEGTA selectively removed ca++- and classical

complement activity, leaving the alternate pathway intact.

Sterile O.lM

MgEGTA was used to chelate reaction mixtures by adding 0.015 ml of this solution to each 0.15 ml of antiserum and complement prior to incubation.
Chelator stock solutions of 0.1 M MgEGTA were prepared by disolving EGTA
in normal saline (0.15M NaCl).

The mixture was heated to 60°C, and 5N NaOH

was added dropwise until EGTA went into solution.
to a final pH of 7.45 with IN HCl.

This mixture was adjusted

Granular MgCl

was then added to the solu2
tion, which was brought to a final concentration of O.lM (MgCl & EGTA) with
2
saline, and autoclaved.
Chemotaxis reaction mixtures
In the preliminary studies, a measured quantity of lyophilized cell wall
sonicate or LPS was diluted in 0.15M veronal buffered saline (VBS), pH 7.3,
to 0.15 ml and incubated with 0.15 ml guinea pig complement for thirty minutes
at 37°C.

The mixture was then removed and heat-inactivated at 56°C for thirty

minutes to prevent any further complement activity.

The mixture was then di-

luted to 1.5 ml in Gey's medium (final serum concentration 10%), and utilized
in a chemotaxis assay (Synderman et al., 1968, 1969; and Keller et al., 1976).
In the normal immune serum reactions, 50 µg of LPS in 0.15 ml VBS was
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incubated with 0.15 ml guinea pig complement and 0.15 ml anti-V. alcalescens
sera (diluted to 0.48 ml with VBS) for thirty minutes at 37°C.

This was fol-

lowed by heat-inactivation at 56°C for thirty minutes, dilution to 1.5 ml in
Gey's medium, and measurement of chemotactic activity.

In reactions of che-

lated serum, 50 µg LPS diluted in 0.15 ml VBS was incubated with 0.165 ml of
chelated guinea pig complement and 0.165 ml of chelated anti-V. alcalescens
sera for thirty minutes at 37°C.
for chemotactic activity.

These mixtures were inactivated and measured

All reaction mixtures in this series of experi-

ments had a final serum concentration of 20% (Keller et al., 1976).

Controls

consisted of normal and chelated serum samples mixed with 0.15 ml VBS in place
of endotoxin.

They were incubated, heat-inactivated, and assayed for chemo-

tactic activity.
Quantitation of chemotaxis
Measurement of complement activation was quantitated using a modified
Boyden diffusion chamber (Neuroprobe, Inc., Bethesda). Permeable 8 micron and
impermeable 0.45 micron Millipore filters were used to separate the two chambers of this chemotaxis assay system.

Prior to assembly of the diffusion

chamber (figure 4), the filters were thoroughly soaked in Gey's medium
to prevent the entrampment of air between them.

They were immediately placed

in the filter retainer groove, and the filter retainer was carefully screwed
into place.

Approximately 1 ml of chemotactic mixture was placed, with a

Pasteur pipet, in the lower compartment of the chamber, which was tilted to
remove any air bubbles collecting at the lower (0.45 micron) filter surface.
The prevention of leakage into the upper compartment assured proper positioning
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Chemotactic solution

\
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PMN leukocyte solution

/

Teflon
plug

13 mm diameter
side view

Che~otactic---\~----()
mixture
,

~roove for filters. 8 micron
filter placed
above .45 micron filter.

\

Leukocyte
suspension
top view

FIGURE 4
Modified Boyden Diffusion Chamber

35
of filters.

Immediately following, 0.56 ml of the leukocyte suspension was

placed in the upper chamber compartment (teflon filter retainer) simultaneous
with the placement of the remaining chemotactic mixture in the lower compartment.

The solutions in both compartments allowed a very slight overflow,

which resolved fluid levels and reduced
to hydostatic pressure.

va~iability

in leukocyte migration due

The charged Boyden chambers were incubated for sixty

minutes at 37°C with precautionary measures taken to prevent vibrations and
movement

(Keller et al., 1972, 1976).

Assessment of chemotaxis was measured by the direct quantitation of PMNs
which migrated across the Millipore filters.

The filters were removed to-

gether from the chamber, gently rinsed in Gey's medium, placed on a standard
microscope slide, and stained by the following procedure: 5 minutes fixation
in 85% ethanol, rinse in distilled H 0; separate filters with the lower sur2
face of the 9 micron filter facing up, stain with hematoxylin 5 minutes, rinse
in distilled H 0; dehydration with 70% ethanol (2 minutes), 95% ethanol (2
2
minutes), and absolute ethanol (3 minutes). The filters were then cleared in
xylene and mounted with permount (Fischer).

The number of PMNs that complete-

ly migrated through the filters were counted in ten random fields on the extreme lower surface of the 8 micron filter and on the upper surface of the
0.45 micron filter.

The cells were counted under high power (43x) with the

aid of a microgrid.

The mean and probable error of measurement (P.E.M.) was

calculated for each test and control.

A between-within analysis of variance

was computed between each test and control in both the chelated and normal
serum samples.

In addition, the same statistical analysis was computed be-

tween the normal reaction mixtures and the chelated mixtures to determine the
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difference, if any, in chemotaxis generated from the alternate complement
pathway, with and without classic pathway activation.
The Boyden chambers were completely disassembled and scrupulously cleaned following each chemotaxis assay.

They were rinsed in tap, de-ionized,

and distilled water, and allowed to dry in a relatively dust free environment under an ultra-violet light hood.

Prior to each days use, they were sub-

mitted to ultra-violet radiation for three hours.
Measurement of residual hemolytic complement activity
Residual levels of hemolytic complement in chelated and normal serum were
measured and reported in C 1 H50 units according to the method of Mayer (Kabat
and Mayer, 1961).

These experiments were performed by allowing the desired

amount of antigen (LPS) and antibody react with a large quantity of complement.

At the end of the fixation period, accurately measured aliquots of the

reaction mixtures were measured for hemolytic complement levels by a photometric procedure.

Sheep red blood cells were sensitized with rabbit anti-

sheep hemolysin (Difeo).

This was accomplished by harvesting fresh red blood

cells from sheep blood, which were suspended in VBS at 5 x 10 8 per ml with the
use of a hemacytometer.
per ml.

These cells were subsequently concentrated to 1 x 10 9

The cells were optimally sensitized by the addition of 12.5 ml of a

1:400 dilution of anti-sheep hemolysin to 12.5 ml of red cells, which brought
the final concentration to 5 x 10 8 per ml.

This mixture was gently agitated

for 5 minutes, and then incubated for sixty minutes at 37°C.
A 2.5 ml dilution of 50 µg LPS in VBS was mixed with 5.0 ml of a 1:10
dilution of complement and 2.5 ml of a 1:10 dilution of anti-V. alcalescens

37
sera.

Two identical 10 ml reaction mixtures were prepared with 50 µg of LPS

in similar 1:10 dilutions of chelated complement and chelated antisera. Controls consisted of VBS substituted for LPS in all three reaction mixtures.
All components were accurately measured and combined at 4°C (to retard activity), and were incubated for ninety minutes at 37°C in a water bath.

At

the end of the incubation period the tubes were removed, placed in an ice
bath, and prepared for measurement of hemolytic activity.

Both 4.0 and 5.0

ml quantities of a 1:10 dilution of each reaction mixture and control were
placed in sterile tubes, diluted to 6.5 ml with VBS, mixed with 1.0 ml of
sensitized sheep red blood cells, and incubated for ninety minutes at 37°C.
Dilution blanks with 1.0 ml red blood cells and 6.5 ml VBS were also incubated for ninety minutes.

One set of chelated reaction mixtures and con-

trols were recalcified with sterile CaC1 2 solution at a final concentration
of lOmM, prior to mixture with the amboceptor.
At the conclusion of the incubation period, all the tubes were removed
and centrifuged at 160 x g.

The supernatant of each tube was removed, and

the optical density (O.D.) of oxyhemoglobin was read at a wavelength of
550 mµ in a Coleman Jr. spectrophotometer.

The supernatant from the red

cell VBS blanks was used as the blank in the readings of O.D.

A reading was

made of a 1:10 dilution of complement and antisera against a saline blank to
determine a correction factor for serum absorbance.

The per cent lysis of

5 x 10 8 cells/ml was determined by dividing the corrected O.D. of reaction
mixtures by the O.D. of 100% lysis.

The latter was produced by freezing and

thawing 1.0 ml of sensitized cells in 6.5 ml of VBS three times.

The per

cent lysis was transformed into C1 H units from published values (Kabat and
50
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Mayer, 1961) based on the von Krogh equation, x=K(y/1-y)l/n(mathematical expression of the sigmoidal response curve of hemolytic complement activity).
These residual complement levels represent a control for the chelation of
serum by EGTA in the chemotaxis assay.

Results
Activation of complement chemotactic factors in the absence of immune sera
Chemotaxis of leukocytes in a Boyden diffusion chamber is the most
sensitive assay of biological activity generated from complement activation (Synderman et al., 1968, 1969, 1971, 1975).

It quantitatively meas-

ures reaction products and activity, where immune hemolysis and the C3 to
C9 assay qualitatively measure the small percentage of complement capable
of effecting the lysis of sensitized erythrocytes.
To insure accurate measurement of chemotaxis, only those cells which
completely migrated through the 8 micron filter were counted.

The cells

on the lower surface of the filter were observed to have distinct segmented and lobulated nuclei, with the entire cell outline visible (figure 5).
Cells in lower planes (focusing down from the lower surface) were undergoing diapedesis within the pore of the filter, and only varied shapes of
the nucleus could be discerned.

In addition, cells that completely mi-

grated through the filter and became detached, were collected on the 0.45
micron filter.

These varied from 5 to 30% of the total leukocytes counts

in text mixtures, but accounted for only 0-5% in controls.

All readings

were reported as the mean of ten random high power fields ± the probable
error of measurement (P.E.M.).

The latter represents possible error in

the readings due to judgement of the operators decision of whether a cell
was within the plane of measurement or slightly below (within a pore).
These are random errors associated with measurement, and are systematic.
39
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rigure 5. PMN leukocytes on the lower surface of
an 8 micron pore Millipore filter following incubation in the Boyden chamber (43 x).
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Thus, if further measurements of 10 random fields were made, 50% of the
readings should fall within the stated measurement± P.E.M. (Parratt, 1961).
Varying quantities of

y_. alcalescens Cl cell wall material ranging

from 5 µg to 5 mg were incubated with guinea pig complement in chemotaxis
assays.

Although these were somewhat arbitrary units, their usage was

loosely based on previous findings of
pilot studies using

!·

coli activation of complement and

!· coli LPS and Veillonella cell walls at concentrations

between 0.5 µg and 500 µg (Fine, 1974). Activation of complement by cell
wall material was evident in the increases of directed migration of PMNs
(figure 6).

The number of migrating cells almost doubled from 5 µg to 500

µg, compared to minimal increases of 90.3 ± 4.5 to 103.4 ± 7.5, for cell
concentrations between 500 µg and 5 mg.

This is consistent with published

data on complement activation in which LPS-generated chemotaxis reaches a
plateau with increasing amounts of activator (Synderman et al., 1968). Controls for these experiments were consistent with readings between 28.9 ±
1.6 and 35.l ± 1.5.

These numbers express the random migration of leuko-

cytes occuring throughout the incubation period.

In statistical analysis,

all test mixtures differed from positive controls with P < .01.

Thus V.

alcalescens Cl, the rumen strain, can generate complement chemotaxis similar to the oral strains.

Strain Cl has a typical cell wall structure and

chemical composition for Veillonella species (Winter & Delwiche, 1975), and
also possesses biologically active lipopolysaccharide in that structure.
The endotoxin extracted from Veillonella appeared to compose a very
small quantity of the whole cell dry weight (1.7%).

This does not neces-

sarily reflect weak endotoxic activity in V. alcalescens (Bladen et al.,

Figure 6
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1965; and Mergenhagen et al., 1961).

The purified material was readily sol-

ubilized in distilled water, and adhered tenaceously to sheep red blood
cells (for hemagglutination) at concentration of 50 µg per ml.

An insolu-

ble preparation of LPS would have indicated complexing with divalent cations (Ca-I+ and Mg-I+) and an inability to generate significant biological
activity (Shands, 1971).
The purified endotoxin effected complement-mediated chemotaxis in concentrations from 0.05 µg to 50 µg.

Both 0.05 µg and 0.5 µg produced simi-

lar migrations of PMNs (62.9 ± 3.9 and 60.3 ± 5.1), as did 5.0 µg and 50 µg
(88.8 ± 5.6 and 102.5 ± 5.1).

Although there was not as dramatic a differ-

ence within this series of experiments as with those from cell wall studies,
they demonstrated a consistent ability to generate complement-mediated chemotaxis in a Boyden system, with results comparable to or greater than those
observed for cell wall material at hundred-fold higher concentrations.

The

controls varied slightly, from 16.9 ± 2.1 to 41.2 ± 1.4, but were all significantly less than the test reading with P < .01.
Based on this quantitation of complement chemotaxis for varying amounts
of endotoxin, 50 µg was chosen as the quantity to activate immune and chelated test mixtures.

This corroborates previous findings on the ability

of the LPS of oral Veillonella strains, Serratia marcesens, and Salmonella
species to generate maximum chemotaxis from a fixed quantity of guinea pig
complement (Synderman et al., 1968, 1969; Mergenhagen et al., 1969; and
Gewurz et al., 1971).
LPS-chemotaxis in immune and chelated immune sera
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Eight in vitro immune reaction systems containing 50 µg LPS, anti-V.
alcalescens sera, and complement, were tested and compared to eight identical reactions mixtures with MgEGTA chelated anti-sera and complement
for stimulation of chemotaxis (table 2).

The normal serum reaction varied

from 85.2 ± 4.5 to 227.4 ± 16.2 but not significantly enough to effect its
relation to data on the chelated reactions (variance within the sample).
The chelated reactions mixtures also had a varied sampling, from 60.1 ±
12.2 to 204.7 ± 18.6.

There was very little variation in the normal con-

trols (from 22.2 ± 2.5 to 38.8 ± 3.1), which were significantly less than
the chemotaxis in the reaction mixtures (P

.S. .001). Variation in the che-

lated controls was greater than that in samples previously examined (11.7

± 1.4 to 81.3 ± 8.8).

The controls were also significantly less (P < .001

for 1, 2, 3, 4, 5, 8, and P < .05 for 7 and 6) than reaction mixtures. Chelation was performed with MgEGTA because of its ability to remove ca++,
causing the disassociation of the Cl complexes, and the negation of classic
complement activity with alternate pathway intact (Fine, 1972, 1974; and
Forsgren et al., 1975).
The chelated immune system generated chemotaxis in eight separate tests
(mean= 94.6 ± 7.1) to levels which were not significantly different from
the experiments with normal complement and anti-sera (108.7 ± 8.9). The
latter is in a system in which a significant titer of immunoglobulin was
reacting with an antigen and forming complexes capable of initiating classic complement fixation, while the alternate complement pathway was being
effected. Thus, the alternate pathway in chelated serum can, in fact, generate biologically active products (C3a, C5a, C5b-6-7) for chemotaxis as
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Table 2
Quantitation of Chemotaxis in Normal & Chelated Serum
Mean PMNs/10 fields±P.E.M.
Test

50µg LPS
normal

50µg LPS
chelated

Normal
control

Chelated
control

1

143.9±8.3

119.2±4.1

29.4±3.4

11. 7±1.4

2

90.0±6.4

121. 3±6. 6

23.7±1.7

12.7±2.3

3

85.2±4.5

204.7±18.6

23.3±2

81. 3±8. 8

4

139.3±8.8

184.2±5.2

37.8±3.l

27.0±2.6

5

227.4±16.2

108.6±13

34.3±4.4

22.1±3.9

6

132.3±13.2

59.3±3.3

30.7±2.l

35.1±3.7

7

147. 3±21.1

79.6±7.6

22.2±2.5

43.7±4.5

8

121. 2±10.5

69.1±12.2

37.3±2.4

21.1±1.4

Quantitation of leukocytes in normal serum assayed 50 µg LPS as an
activator of 0.15 ml anti-V. alcalescens and 0.15 ml complement. The
chelator measurements were-assays of 50 µg LPS with chelated antisera
and chelated complement. Controls substituted 0.15 ml VBS for the LPS.
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quickly and efficiently as the classic and alternate systems together (in
fixed amounts of LPS, antibody, and complement).
Measurement of residual hemolytic activity
Hemolytic titers of complement were measured by an assay to determine
the effect of chelation with MgEGTA on classic complement fixation.
experiments measured the number of C'H
reaction mixture after incubation.

50

These

units present in a dilution of

In reaction mixtures with 50 µg LPS,

normal antisera, and complement, residual hemolysis was negligible (table
3) ,whereas complement controls with antisera and VBS had a mean 37.5 C1 H
50
units.

Thus in normal serum reaction mixtures with 50 µg of endotoxin,

hemolytic levels were reduced to a negligible level.

The control levels

represent the complement hemolytic unit in all reaction mixtures prior to
incubation.
Chelated reaction mixtures and controls effected no hemolysis, due to
the removal of Ca++ ions and negation of classical complement activity.
However, the recalcification of chelated reaction mixtures and controls,
prior to incubation with amboceptor, retained classical activity.

The re-

action mixture with LPS had a mean 6.4% hemolysis (negligible C 1 H
units),
50
while the recalcified control had a measurement of 44.4 units (48.1%).
The activated recalcified mixture had a significantly low titer of hemolytic
complement activity, though slightly above the normal serum reaction mixture.

Hence, chelation with MgEGTA removed classic complement activity from

serum reaction mixtures, which could be reactivated by saturation with Ca++.
The small, almost insignificant, hemolytic levels of recalcified LPS-acti-

Table 3
Residual Hemolytic Activity of Normal & Chelated Serum*

Reaction
Mixture

Mixture
for
Hemolytic Estimation
Diln
Vol.

C', VBS, & antiserum

Hemolysis
%

units

4.0
5.0

25.7%
30.7%

LPS,C', & antiserum

4.0
5.0

1. 9%
1.4%

Chelated C', & antiserum
LPS, chelated C', &
antiserum

4.0
5.0
4.0
5.0

0
0
0
0

4.0
5.0
4.0
5.0

47.6%
48.6%
8.5%
4.3%

1:10

Recalcified C', &
antiserum
Recalcified C', LPS
& antiserum

1:10

1:10

Residual
c'H50

32.4
42.5

39.3
49.5
Neg.
Neg.

Neg = negligible
* As explained in text

~

......

48
vated reaction was due to LPS consumption of the six terminal components.
This corroborates previous studies in which LPS of V. alcalescens and E.
coli reacted with large amounts of the six terminal complement components
in normal and chelated serum (Synderman et al., 1968; Gewurz et al., 1968;
and Fine, 1974).

This measurement of residual hemolytic complement was

made as a control of the effect of chelation with MgEGTA.

DISCUSSION
The objective of this study was to compare the ability of two
LPS-activated complement pathways to effect chemotaxis of PMN leukocytes.

This was done by activating the classic and alternate pathways

in one series of reactions, and comparing them to chelated reactions
which exhibited the activity of the alternate pathway.

This direct

measurement of complement chemotactic factors has been reported to
be the most significant assay of the use of terminal complement components.

Previous studies reported the ability of LPS to consume

greater amounts of the six terminal complement components than zymosan,
inulin, or immune complexes (Synderman et al., 1968, 1969; and Gewurz
et al., 1968).

However, classic complement activity generated by im-

mune complexes could not be compared to alternate pathway activity (LPS,
inulin, and zymosan) in the production of C3a, C5a, and CSb-6-7, due to
the inefficiency of measuring C1 H units in these experiments. In the
50
kinetics of complement hemolysis, only 10 to 20% of C3b and C5b are retained on the red cell membrane for construction of the attack unit, and
can not be used to determine active cleavage products in the fluid phase
(Rapp & Boros, 1970; Kabat & Mayer, 1961; and Mayer, 1970).

Thus, the

data of this study has particular importance for the function of the alternate pathway in the production of biologically active products.
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The chemotaxis and hemolysis experiments do not directly measure
or describe the molecular consequences of classical or alternate complement activation, but they do provide evidence dependent on the efficiency of the two pathways to consume the six terminal complement
components.

There was a slight difference between the low levels of

hemolysis in the normal reaction mixtures, but may have been the result of unused Cl, C2, and C4 in the latter.

The ability of LPS-

activation of the alternate pathway to consume significantly large amounts of C3 to C9 corroborates evidence of the ability of

!· coli and

V. alcalescens LPS to produce the same results (Synderman et al., 1968;
and Fine, 1974).

Classic complement pathway activation relies on the

correct spacial arrangement of IgG for contact with Clq (IgGn , n>l).
However, the ever-increasing number of alternate pathway activators represents a more general and nonspecific complement activation that has
been demonstrated in this study to equal the classic and alternate systerns together.

Thus, the alternate complement pathway equals the clas-

sic pathway in the efficiency of activation and consumption of the six
terminal components.

This could be due to the numerous repeating subu-

nits in the lipid A portion of LPS available for contact with IF of the
properdin system.

This reaction is analogous to IgGn -Clq contact, but

does not require specificity such as the Clq-receptor in the Fe fraction of immunoglobulins (Muller-Eberhard, 1975).

The two pathways, thus,

function as equal effector systems in producing biologically active products in nonspecific and specific reactions.
Endotoxin has been shown to cause the directed migration of blood
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leukocytes through the activation of a complement peptide, C5a (Synderman et al., 1968, 1969, 197la, and 1972; Shin et al., 1968, 1969; Gewurz
et al., 1971; Kay & Austen, 1970).

PMN leukocytes, monocytes, eosino-

phils, and basophilic leukocytes are attracted to this factor, which
also possesses anaphylactic ability with C3a (Jensen et al., 1969). The
inability of CS-deficient mice to hault bacterial infection following
the primary lodgement of organisms is a further example of the importance of biologically active complement peptides participating in host
defense mechanisms.

These two minor complement peptides were also de-

termined to possess chemotactic activity for PMNs.
Complement components C3a and C5a generated by either pathway were
also identified as principle anaphyltoxins, which degranulate mast cells
and basophils, cause increased vascular permeability, smooth muscle contraction, and the extravasation of fluids from vessels (Gewurz et al.,
1971; Hook et al., 1970; Dierich et al., 1973; Muller-Eberhard, 1975; and
Ward, 1971).

Many pathological features of endotoxin-complement reac-

tions in experimental animals are present in the Arthus phenomenon, and
can be simulated by immune complexes (Jensen et al., 1969; and Stetson,
1964).

Thus, C3a and C5a function in both immune and innate reactions

in host defense mechanisms by mediating the inflanunatory response.
The in vitro activities of LPS-complement chemotaxis have been related to the in vivo inflanunatory effects caused by the experimental injection of LPS and purified CSa.

The injection of endotoxin causes a

number of pathological occurences dependent on the function of a viable
complement system (Thomas, 1954; Gewruz et al., 1970; Pearlman et al.,
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1963; and Mergenhagen et al., 1969).

These reactions include local skin

inflammation with intravascular coagulation, PMN accumulation, vasculitis, and necrosis (Greisman, 1960; and Stetson, 1951).

These reactions

were mediated via principle biologically active peptides cleaved from
LPS-activation of the alternate complement pathway (Mergenhagen et al.,
1973; and Gewurz et al., 1971),
The chemotaxis experiments of this study corroborate previous data
of the production of biologically active C5a in both classic and alternate pathway in vitro systems, and suggest that the alternate pathway can
produce in vivo chemotactic and anaphylactic factors in reactions equal
to those produced with two functional complement pathways.

The alter-

nate pathway could mediate an inflammatory response identical to classic
complement amplification of an immune response, and preceed the latter
in certain infections as a primary humeral defense mechanism.
The presence of C3a, C5a, and C5b-6-7 in human pathological fluids,
serum, and experimental vasculitis has indicated the ability. of complement chemotactic factors to mediate inflammation and the in vivo accumulation of leukocytes in causing tissue destruction (Mergenhagen et al.,
1972; Muller-Eberhard, 1972a; and Ward, 1971).

Phagocytosis of comple-

ment-tagged (C3b) particles by leukocytes results in degranulation of the
leukocytes and release of proteolytic enzymes capable of causing connective tissue damage, extravasation of plasma, and Arthus vasculitis.

~ur

therrnore, the attraction of PMNs to alternate pathway produced factors
has been shown to cause selective enzyme release in the absence of spe-
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cific particles.

It has also been found that if the PMN plasma membrane

is perturbed sufficiently, pertubation, fusion, and extrusion of enzymes
occurs through a process of reverse endocytosis (Goldstein et al., 1973).
The interaction of C5a and the PMN membrane has caused the release of lysozyme, S-glucuronidase, and microtubule assembly.
pende~t

In vivo, this is de-

on phagocytosis or adherence to complement opsonized particles

(Goldstein et al., 1975).

It is probable that the classic activation of

complement can function as an effector of immune tissue destruction
through the accumulation and degranulation of PMN leukocytes.

In addi-

tion, the alternate pathway could also function in nonspecific tissue
destruction that preceeds any immune involvement, and would act synergistically with the latter, upon prolonged exposure, in tissues susceptible to damage by inflammatory products.
Solid evidence for the role of the alternate pathway in disease,
in the absence of classic pathway activation, is difficult to obtain due
to the potential of classic generated C3b, which could react with Pa and
bind P if deposited on a membrane (Gotze & Muller-Eberhard, 1976). However, in cases where the alternate pathway functions in tissue injury,
it could act either as the principal complement effector, or produce biologically active products with the classic pathway (Naff, 1972).

The ana-

phylactic and chemotactic activities of C3a and C5a in initiating and sustaining inflammation are simultaneous with the opsonization of particles
or membranes with C3b to facilitate adherence to the accumulating leukocytes, and enhancing phagocytosis (Jensen, 1969).

Thus, the presence of
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a powerful complement activator, such as bacterial endotoxin, in either
initial or prolonged exposure, could result in the continual production
of inflammatory products.

This tremendous inflammatory.response could

mediate tissue destruction, and is of particular importance in tissues
suceptible to damage from inflammation (Lepow, 1972; Synderman, 1972a;
and Muller-Eberhard et al., 1973).

These are reactions in which immuno-

globulin production would not necessarily be critical for optimum complement activation and production of phlogistic products.
The interaction of endotoxin with complement, innately or in the
presence of immunoglobulins to specific "O" antigens, may be implicated,
partially, in the etiology of soft and hard periodontal tissue destruction.

Low, but biologically significant levels of LPS have been demon-

strated in plaque as well as in Gram-negative bacteria isolated from plaque
(Berglund et al., 1969; and Mergenhagen et al., 1961).

Although the great-

er per centage of cultivable bacteria in the normal gingival crevice are
Gram-positive rods and cocci (Actinomyces and Streptococcus species), Gramnegative anaerobic rods and cocci (Veillonella, Fusobacterium, and Bacteroides) compose approximately 28% of the cultivable flora (Socransky, 1970).
Veillonella species have been found to occur in subgingival plaque up to
8% of the cultivable flora, while Gram-negative rods range from 6.5% to
61.2% after sixteen days of growth (Stig et al., 1976).

Thus, subgingi-

val plaque is a good source of bacterial endotoxin.
Crevicular material and plaque extracts in clinically healthy individuals harbor factors chemotactic for PMNs that are heat labile

SS
at S6°C, and can induce experimental vasculitis (Hellden & Lindhe, 1973;
Tempel et al., 1970; Egleberg, 1967; Kahnberg, 197S; Lindhe & Hellden,
1972; and Miller et al., 197S),

The additional finding of C3 and C4 in

clinically healthy gingival crevices, and C3pa and CS in chronically inflanuned gingivae, indicates that complement is quite active in gingival
inflanunation (Attstrom et al., 197S; and Shillitoe & Lehner, 1972). Decomplementation of Labrador Retrievers prior to topical application of
plaque extracts failed to initiate vasculitis observed in the experimental initial gingivitis in the control dogs (Kahnberg et al., 1976).
The presence of endotoxin in the cell walls of Veillonella, Fusobacterium, and Bacteroides species found in subgingival plaque could account for
some of the complement activation in both initial gingivitis and chronic
periodontal disease.
Previous clinical studies have suggested a relationship between oral
endotoxin levels and the severity of gingival inflanunation (Simon et al.,
1970, 1971, and 1969).

The resultant tissue damage could be mediated via

the complement cleavage of CS (Porter et al., 1971; Sarknes, 1966).

In-

creases in the levels of endotoxin in crevicular exudate, dental plaque,
and gingival tissue have been

~orrelated

to the degree of clinical inflam-

mation in periodontal patients (Shapiro et al., 1972).

Increasing gingi-

val index scores have also been shown to accompany increases in endotoxincontaining Gram-negative bacterial cells in plaque, including Veillonella
species (S to 2S%) (van Palenstein & Hoogeveen, 1976; and Johnson et al.,
1976).

The potent ability of oral Veillonella endotoxins to activate com-

plement in vitro and generate significant chemotaxis can be related to in
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vivo inflarmnation in periodontal tissues (Synderman et al., 1969, 1972a).

v.

alcalescens Cl is similar in the structure of its cell wall and lipo-

polysaccharide to the various oral strains under study (Mergenhagen et al.,
1969; Synderman et al.,. 1968; and Mergenhagen et al., 1961).

The actual

form of endotoxin in the sulcular environment is probably closer to that
of a lysed cell wall fragment, rather than the purified soluble product.
This study has demonstrated the ability of those LPS-containing cell wall
fragments to activate complement chemotaxis in various quantities.

Thus,

the activity of the extracted LPS can be related to the cell wall particle.
The data of this study is of special interest in acute periodontal inflaI!j11J,ation and soft tissue destruction.

Initial acute gingivitis could

occur through the interaction of endotoxin with complement in the absence
of a significant titer of antibody.

Through the mechanical irritation of

plaque, calculus, and bacterial enzymes, endotoxin-containing cell wall
particles could penetrate crevicular epithelium for immediate contact with
complement components and activation of the alternate pathway.

The data

of the chemotaxis experiments emphasize the extent of this initial complement activation as being equal to an immune response, which would occur
over a longer period of time (5 to 14 days), upon primary exposure of this
antigen.

The biological effects in causing vascular permeability, smooth

muscle contraction, mast cell degranulation, and chemotaxis of PMNs and
monocytes are relevent to the onset of periodontal inflarmnation.

The sub-

sequent phagocytosis and metabolism of leukocytes would result in lysosomal
release of enzymes, including cathepsins and collagenases (Cochrane, 1968).
Thus, the products in plaque, rather than the organisms themselves, may in-
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itiate a chain of molecular events resulting in the progressive destruction of supporting periodontal structures.
The accumulation and degradation of leukocytes would cause initial
tissue destruction, the breakdown of intracellular substances (desmosomes
and hemidesmosomes), and the further penetration into gingival epithelium
and lamina propria of endotoxin and other bacterial antigens.

The latter

has been demonstrated with purified LPS in experimental gingivitis, and
has been observed in gingival biopsies of patients with periodontal disease
(Schwartz et al., 1972; Tempel et al., 1970; and Shapiro et al., 1972).
The prolonged exposure of LPS and stimulation of immune mechanisms would
not necessarily increase inflammatory products, according to the in vitro
measurements of chemotaxis in the immune and non-immune systems.

However,

as the disease progresses, the environment becomes more favorable for anaerobic organisms, which includes the LPS-containing Gram-negative species.
The accompanying increases in LPS lead to the further progression of periodontal inflammation, but does not necessarily depend on immunoglobulin production.

Thus, the initial exposure of small amounts of endotoxin-contain-

ing particles are sufficient to activate complement and cause inflammation
and tissue destruction.

This cycle of LPS and antigen penetration, expo-

sure to immune and non-immune host defenses, and inflammation would become
self-sustaining, and lead to the further progression of the disease process.
In chronic periodontal inflammation, the large amounts of endotoxins
found in pocket formation could be constantly activating complement through
both pathways, and producing factors to act synergistically with lyrnphokines
in the chemotactic attraction of monocytes and eosinophils (Kay et al.,1975).
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The resultant bone resorption accompanying chronic inflammation could also
be influenced by complement activation (Synderman, 1972).

The release of

heparin from connective tissue mast cells in regions of alveolar bone
could cause bone resorption.

Heparin had been shown to act synergistically

with gingival tissue fragments in enhancing in vitro bone resorption (Goldhaber, 1965, 1971).

Lyososomal enzymes, derived from inflammatory leuko-

cytes, also have been shown to stimulate in vitro bone decalcification
(Fell, et al., 1966).

Lastly, endotoxin has been found to directly in-

hibit bone growth and stimulate chondroclast resorption in tissue culture
(Hauseman, et al., 1970),

Thus, endotoxin-complement generation of bio-

logically active products are probably responsible, in part, for periodontal tissue destruction in acute and chronic inflammation through innate
or immune mechanisms.
The objectives of this study have been fulfilled: the chemotaxis in
two complement pathways was studied with the alternate pathway solely, and
was supported by a subline of evidence in residual hemolytic complement
measurements; and this in vitro function has been related to possible in
vivo effects of the production of phlogistic peptides.

SUMMARY

The cell wall and endotoxin extracted from Veillonella alcalescens
activated· the alternate complement pathway and produced chemotactic factors for polymorphonuclear leukocytes.

The purified endotoxin generated

chemotactic activity from whole guinea pig serum in reactions equal to
chemotaxis with one hundred fold greater amounts of cell wall material.
Therefore, the major complement activating ability of

'Y..· alcalescens

cell walls is due to the biologically active endotoxin.
Lipopolysaccharide-activated complement measured in immune and nonimmune reaction mixtures showed no significant differences in the chemotaxis of PMNs between the alternate pathway, solely, and both active complement pathways together.

This establishes non-immune alternate path-

way activation as an equal biological effector to immune activation of
the classic pathway in the production of factors which mediate the inflammatory response.
Endotoxin-complement activation is significant in tissues susceptible to damage by the inflammatory response.

The continual presence

and infiltration of Gram-negative bacteria and endotoxin in the healthy
human gingival sulcus is a factor in the initiation of periodontal disease through alternate complement pathway activation, subsequent accumulation and degradation of PMNs and monocytes, epithelial tissue destruction, and further antigen penetration to underlying lamina propria with
immunocompetant cells.
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